论文部分内容阅读
通过对环氧化酶-2(COX-2)、雌激素受体(ER)、孕激素受体(PR)及C-erbB-2在人乳腺癌的表达及其相互关系研究,进一步探讨COX-2在人乳腺癌发生、发展中的作用及临床意义。方法采用免疫组化方法检测49例人乳腺癌组织标本中COX-2、ER、PR及C-erbB-2的表达情况,分析COX-2在乳腺癌中的表达特征,并分析COX-2与ER、PR及C-erbB-2相互关系。结果49例人乳腺癌组织标本中COX-2表达阳性率61.22%,与肿瘤分期无关(P>0.05);与淋巴结转移阳性显著相关(P<0.005)。COX-2的表达与ER、PR阴性状态有相关性(P<0.05)。ER、PR阳性表达有同步性。C-erbB-2的阳性表达率59.18%,C-erbB-2的表达与淋巴结转移阳性者有关(P<0.005)。在C-erbB-2阳性的29例中COX-2表达阳性率79.31%,而C-erbB-2阴性的20例中COX-2表达阳性率35%,两者相比有显著差异性(P<0.005),COX-2的阳性表达与C-erbB-2的阳性表达有相关性。结论COX-2在人乳腺癌组织中呈高水平表达。COX-2在乳腺癌的发生、发展和转移中可能起重要作用。在检测乳腺癌淋巴结转移、ER,PR和C-erbB-2等生物学指标的同时,联合检测COX-2的表达,能更好地评估乳腺癌的进展情况和预后,并为应用选择性COX-2抑制剂防治乳腺癌提供了依据。
The expression of cyclooxygenase-2 (COX-2), estrogen receptor (ER), progesterone receptor (PR) and C-erbB-2 in human breast cancer and their relationship were further explored -2 in the occurrence and development of human breast cancer and its clinical significance. Methods The expression of COX-2, ER, PR and C-erbB-2 in 49 specimens of human breast cancer were detected by immunohistochemistry. The expression of COX-2 in breast cancer was analyzed. The expressions of COX-2 and ER, PR and C-erbB-2 correlation. Results The positive rate of COX-2 expression in 49 cases of human breast cancer specimens was 61.22%, which was not related to tumor stage (P> 0.05). The positive rate of COX-2 was significantly correlated with lymph node metastasis (P <0.005). COX-2 expression and ER, PR negative correlation (P <0.05). ER, PR positive expression of synchronization. The positive rate of C-erbB-2 was 59.18%. The expression of C-erbB-2 was correlated with lymph node metastasis (P <0.005). The positive rate of COX-2 in C-erbB-2 positive cases was 79.31%, while the positive expression rate of COX-2 in C-erbB-2 negative cases was 35% (P <0.005). The positive expression of COX-2 correlated with the positive expression of C-erbB-2. Conclusion COX-2 is highly expressed in human breast cancer tissues. COX-2 may play an important role in the occurrence, development and metastasis of breast cancer. Detecting the lymph node metastasis of breast cancer, ER, PR and C-erbB-2 and other biological indicators, combined detection of COX-2 expression, can better assess the progress of breast cancer and prognosis, and for the use of selective COX -2 inhibitors provide a basis for prevention and treatment of breast cancer.